TTFields exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death. "The CE Mark approval for Optune Lua for metastatic non-small cell lung ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered ... 1 According to the American Cancer Society, lung cancer remains the leading cause of cancer-related death in ...

The drug has been specifically authorised in combination with etoposide and platinum chemotherapy to treat adult patients with extensive-stage small cell lung cancer (SCLC ... in a 25% reduction in ...

Researchers have shown that activation of the protein YAP, which helps tumours grow, differs between two- and three-dimensional culture models, pointing to more predictive systems for testing cancer ...

One clinical trial of Opdivo involved adults with squamous non-small cell lung cancer (NSCLC). Researchers found that people with squamous NSCLC who took Opdivo had a lower risk of death compared ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

An independent data monitoring committee has determined that the HARMONi-6 trial for the first-line treatment of advanced squamous non-small cell lung cancer ... or death in the dual endpoint ...

Another with stage IV small cell lung cancer remained alive 5 months after starting treatment. Two patients survived 2 months before dying. “[I remember] the person I asked to order the drug ...

In announcing (Chinese) ivonescimab’s Chinese approval in first-line PD-L1-positive non-small cell lung cancer on Friday, Akeso noted that the bispecific drug slashed the risk of death by 22.3% ...